De Novo Sphingolipid Biosynthesis in Atherosclerosis
Adv Exp Med Biol. 2022;1372:31-46. doi: 10.1007/978-981-19-0394-6_3.ABSTRACTAtherosclerosis is the formation of fibrofatty lesions in the arterial wall, and this inflammatory state of the artery is the main cause of advanced pathological processes, including myocardial infarction and stroke. Dyslipidemic conditions with excess cholesterol accumulate within the arterial vessel wall and initiate atherogenic processes. Following vascular reaction and lipid accumulation, the vascular wall gradually thickens. Together with the occurrence of local inflammation, early atherosclerotic lesions lead to advanced pathophysiological events, plaque rupture, and thrombosis. Ceramide and sphingomyelin have emerged as major risk factors for atherosclerosis and coronary artery disease. Currently, the clinical association between de novo sphingolipid biosynthesis and coronary artery disease has been established. Furthermore, therapeutic strategies to modulate this pathway, especially those involving serine palmitoyltransferase and sphingomyelin synthase, against atherosclerosis, cancer, type 2 diabetes, and non-alcoholic fatty liver disease are actively under development. In this chapter, we focus on the relationship between de novo sphingolipid biosynthesis and coronary artery disease.PMID:35503172 | DOI:10.1007/978-981-19-0394-6_3
Source: Atherosclerosis - Category: Cardiology Authors: Tae-Sik Park Shivani Devi Amitesh Sharma Goon-Tae Kim Kyung-Hee Cho Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Cardiology | Cholesterol | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Heart Attack | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Stroke | Thrombosis | Urology & Nephrology